相关实验视频

Updated: Jun 28, 2025

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

用组合免疫疗法方法向鼻腔不分化的癌症

Austin T K Hoke¹, Yoko Takahashi², Michelle R Padget³

¹Sinonasal and Skull Base Tumor Program, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, United States.

Translational oncology

|April 9, 2024

概括

这项研究表明,将抗PD-L1阻断与IL-15超激素的结合显著增强了自然杀手 (NK) 细胞杀死鼻腔不分化癌 (SNUC) 细胞的作用. 这些发现支持进一步研究SNUC的免疫疗法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

鼻未分化癌 (SNUC) 是一种罕见的,具有攻击性的癌症,治疗选择有限,预后不佳.
研究新的治疗策略,如免疫疗法,对于改善患者的治疗结果至关重要.

研究的目的:

探索SNUC的组合免疫疗法的潜力.
评估SNUC细胞系对自然杀手 (NK) 细胞基免疫疗法的敏感性.
描述SNUC患者的体内瘤免疫微环境 (TIME).

主要方法:

使用人类衍生的SNUC细胞系进行体外研究,以测试免疫治疗策略.
从14名先前未接受治疗的SNUC患者的瘤样本进行多谱免疫光分析.
评估免疫细胞透和患者结果之间的临床相关性.

主要成果:

抗PD-L1阻塞通过抗体依赖细胞毒性 (ADCC) 增加了约5.4倍的SNUC细胞的NK细胞介导溶解.
与抗PD-L1阻塞和IL-15超激素的联合治疗增强了9.6倍的NK细胞杀死.
在具有良好的临床结果的患者中观察到瘤细胞和NK细胞/CD8+T细胞之间的相互作用增加,包括没有复发和长期幸存者.

结论:

这项研究提供了临床前证据,支持将抗PD-L1阻断与SNUC免疫疗法的IL-15超激素结合的疗效.
这些发现凸显了向免疫检查点和增强SNUC治疗中NK细胞活性的潜力.
对SNUC的组合免疫治疗方法进行进一步的临床研究是有必要的.

关键词:

抗体依赖的细胞细胞毒性在IL-15中,IL-15是最常见的.免疫微环境是一个微环境.免疫治疗是一种免疫疗法.自然杀手细胞是自然杀手细胞.鼻未分化的癌瘤

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...